Rhumbline Advisers Acquires 5,005 Shares of Humacyte, Inc. (NASDAQ:HUMA)

Rhumbline Advisers raised its holdings in shares of Humacyte, Inc. (NASDAQ:HUMA) by 4.6% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 114,455 shares of the company’s stock after purchasing an additional 5,005 shares during the quarter. Rhumbline Advisers owned 0.09% of Humacyte worth $578,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also made changes to their positions in the business. Vontobel Holding Ltd. purchased a new position in Humacyte in the 4th quarter worth about $50,000. Brookstone Capital Management bought a new position in Humacyte in the 4th quarter worth about $56,000. ACT Wealth Management LLC purchased a new position in shares of Humacyte during the fourth quarter worth approximately $57,000. Concurrent Investment Advisors LLC bought a new stake in shares of Humacyte during the third quarter valued at approximately $75,000. Finally, FORA Capital LLC purchased a new stake in shares of Humacyte in the third quarter valued at approximately $96,000. 44.71% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Several research firms have commented on HUMA. Benchmark restated a “buy” rating on shares of Humacyte in a report on Thursday, February 27th. D. Boral Capital restated a “buy” rating and set a $25.00 price target on shares of Humacyte in a research note on Friday. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $15.00 price objective (up from $12.00) on shares of Humacyte in a research note on Friday, December 20th. One equities research analyst has rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, Humacyte currently has an average rating of “Buy” and an average price target of $13.71.

Humacyte Trading Up 4.4 %

HUMA opened at $3.09 on Friday. Humacyte, Inc. has a 12 month low of $2.81 and a 12 month high of $9.97. The stock has a fifty day moving average price of $4.18 and a 200-day moving average price of $4.85. The firm has a market cap of $388.90 million, a price-to-earnings ratio of -2.31 and a beta of 1.36.

Humacyte Company Profile

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.